PharmQuest Corporation Appoints Jerome A. Halperin to its Board of Directors.

Business Editors, Health/Medical Writers

SAN JOSE, Calif.--(BW HealthWire)--April 19, 2001

PharmQuest Corporation announced today the appointment of Jerome A. Halperin to its Board of Directors.

Mr. Halperin will become President and CEO of the Food and Drug Law Institute

(FDLI), a not-for-profit educational organization dedicated to advancing public health, effective July 1, 2001. Prior to joining FDLI, he was the chief executive at The United States Pharmacopeia (USP) and spent six years in the pharmaceutical industry as Vice President -- Technology for CIBA Consumer Pharmaceuticals, a division of CIBA-GEIGY, Inc., now Novartis (NYSE:NVS). Mr. Halperin served as a commissioned officer in the U.S. Public Health Service for 25 years, retiring from government service in 1983 as Acting Director of the FDA's Office of Drugs in the combined National Center of Drugs and Biologics. He is the 2001 Remington Honor Medalist of the American Pharmaceutical Association and the recipient of the 2001 Distinguished Service Award of the Drug Information Association. Mr. Halperin earned a Bachelor of Science in Pharmacy from Rutgers, The State University of New Jersey; a Master of Public Health from The Johns Hopkins School of Hygiene and Public Health; and a Master of Science in Management from the Massachusetts Institute of Technology.

Shankar Hemmady, President and CEO of PharmQuest noted, "We are honored to have Mr. Halperin join PharmQuest's Board of Directors. His wealth of public health experience and his leadership in a number of government agencies and professional organizations are invaluable to PharmQuest as we bring together drug development software solutions in compliance with the latest regulatory guidelines and international standards."

"I am very pleased to become part of the PharmQuest organization," added Mr. Halperin. "PharmQuest is at the leading edge of using the Internet Technology as a medium for solutions to assure that pharmaceutical and biological products and the systems used to develop, test, manufacture, package and label them are in full compliance with the cGMP regulations (current Good Manufacturing Practices) of the United States Food and Drug Administration (FDA). This technology will save time and expense while providing consumers with the comfort of knowing their medicines are of the highest quality."

About PharmQuest

PharmQuest Corporation (www.pharmquest.com) is the pioneer in web-based Drug Development Informatics and is at the forefront of eR&D. eR&D seeks to accelerate drug development via web-enabled tools and software solutions and is gaining wide acceptance among drug industry leaders through company e-initiatives. PharmQuest's unique technologies and services enable drug developers in the Biotechnology and Pharmaceutical industries to access, manage and streamline relevant decision-making information to improve the success rate and speed of drugs to market. In its first year of operation, PharmQuest has partnered with three of the ten largest pharmaceutical companies, including Pharmacia (NYSE:PHA), to achieve its mission of revolutionizing drug product development in the post-genomic era.